CJC-1295 + MK-677 (Ibutamoren) Stack: Complete Protocol

Why Clinicians Stack CJC-1295 with MK-677

CJC-1295 and MK-677 act on two separate receptor pathways that converge on the pituitary somatotroph to release GH. Using both agents at the same time produces a synergistic pulse pattern that neither compound can replicate alone. That dual-pathway approach is the core rationale for this stack.

How the Two Mechanisms Interact

Growth hormone release is governed by a push-pull system. GHRH (growth hormone-releasing hormone) stimulates GH secretion; somatostatin suppresses it. Ghrelin, acting at the GHS-R1a receptor, both stimulates GH release and reduces somatostatin tone simultaneously.

CJC-1295 is a modified GHRH analogue. The Drug Affinity Complex (DAC) version binds albumin in plasma, extending its half-life to approximately 6 to 8 days compared with the 30-minute half-life of native GHRH [1]. The non-DAC formulation (also sold as "Modified GRF 1-29") has a half-life of roughly 30 minutes and produces a more discrete GH pulse when injected acutely.

MK-677 (Ibutamoren) is a non-peptide, orally active ghrelin mimetic that selectively binds GHS-R1a. A Phase II cross-over trial (N=32) published in the Journal of Clinical Endocrinology and Metabolism showed that a single 25 mg oral dose of MK-677 raised 24-hour mean GH concentration by 97% and IGF-1 by approximately 52% compared with placebo, with effects persisting for at least 24 hours [2].

Additive vs. Synergistic Effects

Mechanistically, the two agents work through separate intracellular signaling cascades. GHRH activates adenylyl cyclase via Gs, while ghrelin receptor activation signals through Gq and activates protein kinase C. Animal studies using combined GHRH analogues plus ghrelin agonists consistently show additive or greater-than-additive GH secretion compared with either agent alone [3]. No human RCT has been published specifically for the CJC-1295 plus MK-677 combination, so this claim is drawn from mechanistic and animal data.

CJC-1295 Alone: What the Evidence Shows

Before examining the combined protocol, understanding each compound's individual evidence base is necessary.

Phase II Trial Data for CJC-1295

A randomized, double-blind, placebo-controlled Phase II trial (N=65) published in the Journal of Clinical Endocrinology and Metabolism tested CJC-1295 with DAC at doses of 30, 60, 120, and 250 mcg/kg as a single injection. IGF-1 increased 2- to 3-fold above baseline and remained elevated for 6 to 14 days [4]. Mean IGF-1 AUC was dose-proportional up to 250 mcg/kg. No serious adverse events were attributed to the drug in that trial.

DAC Versus Non-DAC Formulations

The DAC version provides sustained IGF-1 elevation between injections. Twice-weekly dosing at 100 to 200 mcg maintains near-constant IGF-1 elevation for most patients. The non-DAC version (Modified GRF 1-29) produces a sharper, shorter GH pulse and is often preferred by practitioners who want to preserve more physiologic pulsatility, typically injected at 100 mcg immediately before sleep [1].

MK-677 Alone: What the Evidence Shows

MK-677 is the most extensively studied oral GH secretagogue in humans. It is not a peptide chemically, though it is commonly grouped with peptide stacks in clinical practice.

The Landmark 12-Month Trial

A landmark 12-month, double-blind, placebo-controlled trial (N=65 healthy older adults, ages 60 to 81) published in the New England Journal of Medicine showed that daily MK-677 at 25 mg raised IGF-1 by 39.9% and GH AUC by 97.1% compared with placebo [5]. Fat-free mass increased by 1.1 kg (P<0.001). The trial was significant because it demonstrated that sustained oral GH secretagogue therapy was feasible, safe over 12 months, and did not significantly worsen fasting glucose at this dose in this population.

Two-Year Safety Data

A two-year extension of a separate MK-677 trial in older adults with hip fracture (N=292) found no significant increase in fracture-related adverse events or cancer incidence, though insulin resistance did worsen modestly in patients who had pre-existing glucose intolerance [6]. Fasting glucose should always be monitored when using MK-677 for extended cycles.

Effects on Body Composition and Bone

A 12-week randomized controlled trial in obese men (N=24) showed MK-677 at 25 mg daily increased basal metabolic rate by 20% and preserved lean mass during caloric restriction compared with placebo [7]. Bone mineral density improvements have been documented over 12 months in older adults, consistent with the known anabolic effects of the GH-IGF-1 axis on bone [5].

The Combined Stack Protocol

This section presents the HealthRX clinical framework for combining CJC-1295 and MK-677. It is based on the individual trial data above, animal combination studies, and the clinical consensus of the HealthRX physician panel. No head-to-head RCT exists for this specific combination.

Dosing Table

| Agent | Form | Dose | Frequency | Timing | |---|---|---|---|---| | CJC-1295 (with DAC) | Subcutaneous injection | 100 to 200 mcg | 2x weekly | Any time; consistent day/time preferred | | CJC-1295 (without DAC) | Subcutaneous injection | 100 mcg | Nightly | 30 to 60 min before sleep | | MK-677 (Ibutamoren) | Oral capsule/tablet | 10 to 25 mg | Once daily | 30 min before sleep |

Most practitioners choose one CJC-1295 formulation, not both. The non-DAC version stacked with nightly MK-677 is the most common clinical approach because both agents are taken at the same time, producing a coordinated nocturnal GH pulse that mimics the body's natural sleep-associated GH surge.

Cycle Length and Off-Cycle Protocol

A standard cycle runs 12 to 24 weeks. Longer cycles, up to 6 months, have been used in the anti-aging context, but IGF-1 should be checked at 6 and 12 weeks to confirm levels remain within the target range of 150 to 300 ng/mL. Running IGF-1 consistently above 350 ng/mL raises theoretical concerns about insulin resistance and cellular proliferation, though no cancer causation data exist for this stack specifically [8].

After the cycle, a minimum 4-week off period allows endogenous GHRH and ghrelin sensitivity to normalize. Some protocols use 8 weeks off for every 16 weeks on.

Starting Dose Strategy

New users should begin MK-677 at 10 mg nightly for the first 2 weeks to assess appetite stimulation and water retention before titrating to 25 mg. CJC-1295 can start at 100 mcg per injection from week one. This staggered start helps clinicians attribute any early side effects to the correct agent.

Expected Outcomes and Timeline

Outcomes depend heavily on baseline IGF-1, age, diet, training load, and sleep quality. GH is secreted primarily during slow-wave sleep, so sleep deprivation blunts the benefits of this stack substantially.

Weeks 1 to 4

Water retention is common in the first two weeks and typically resolves partially by week 4. Patients often report improved sleep depth within 7 to 14 days of starting MK-677, which is consistent with MK-677's documented effects on REM and slow-wave sleep architecture seen in a trial of healthy young men (N=8) [9]. Appetite increases noticeably in most patients at 25 mg.

Weeks 4 to 12

IGF-1 levels stabilize. Fat-free mass gains become measurable. The 12-month MK-677 trial showed that lean mass gains were greatest in the first 8 weeks and then plateaued [5]. Body fat reduction is modest with this stack in the absence of a caloric deficit. This is not a fat-loss protocol by itself.

Weeks 12 to 24

Patients in extended cycles report continued soft-tissue recovery benefits, improved skin thickness, and joint comfort improvements consistent with GH-related collagen synthesis. These outcomes are subjective and not confirmed by blinded trials for this combination.

Safety Profile and Side Effect Management

Blood Glucose and Insulin Resistance

MK-677 raises fasting glucose in some patients, particularly those with pre-existing insulin resistance. In the 12-month NEJM trial, fasting blood glucose increased by 0.3 mmol/L on average, and insulin increased significantly compared with placebo [5]. Patients with hemoglobin A1c above 5.7% should use MK-677 with caution and closer monitoring. Fasting glucose should be checked at baseline, 6 weeks, and 12 weeks.

CJC-1295 may also reduce insulin sensitivity acutely by promoting GH secretion, since GH is a counter-regulatory hormone that opposes insulin at the receptor level [10].

Water Retention and Edema

Both agents increase extracellular water through IGF-1-mediated sodium retention. Reducing sodium intake to under 2,300 mg/day during the first 4 weeks helps manage this. Edema that does not improve after 4 weeks warrants reducing MK-677 to 10 mg or discontinuing.

Carpal Tunnel Symptoms

Elevated GH and IGF-1 can cause carpal tunnel-like symptoms (paresthesias, wrist pain) due to soft-tissue swelling. This is dose-dependent and typically resolves with dose reduction. If symptoms persist beyond 2 weeks after dose reduction, discontinue and evaluate [10].

Hypothalamic-Pituitary Axis Suppression

Neither CJC-1295 nor MK-677 suppresses endogenous testosterone or the hypothalamic-pituitary-gonadal axis. They act on the somatotropic axis only. Post-cycle recovery of GH pulsatility is generally complete within 4 to 8 weeks of stopping both agents, based on pharmacodynamic modeling of MK-677's half-life of approximately 24 hours [2].

Contraindications

Absolute contraindications include active or history of hormone-sensitive malignancy, uncontrolled type 2 diabetes (A1c above 8.0%), active acromegaly, and pregnancy. Relative contraindications include pre-diabetes, active carpal tunnel syndrome, and concurrent use of exogenous GH, which risks IGF-1 excess [8].

Monitoring Protocol

Baseline labs before starting the stack should include:

• IGF-1 (serum)
• Fasting glucose and hemoglobin A1c
• Fasting insulin (to calculate HOMA-IR)
• Comprehensive metabolic panel
• TSH (thyroid function, since GH affects T4 to T3 conversion)

Repeat IGF-1 and fasting glucose at week 6. Adjust CJC-1295 dose downward if IGF-1 exceeds 350 ng/mL. Repeat the full panel at week 12.

A target IGF-1 of 200 to 280 ng/mL for patients under age 40, and 150 to 220 ng/mL for patients over 50, reflects the upper portion of the age-adjusted normal range without exceeding it. The Endocrine Society clinical practice guideline on growth hormone deficiency uses these reference ranges for therapeutic GH monitoring [11].

Who Is a Reasonable Candidate for This Stack

Adults with documented low-normal IGF-1 (below the 25th percentile for age and sex), confirmed sleep-onset GH suppression, or suboptimal recovery from training despite adequate nutrition may benefit most. The Endocrine Society guideline notes that GH secretion declines by approximately 14% per decade after age 30 [11], making the rationale for GH secretagogue use more defensible in patients over 35.

Patients should have no contraindications, agree to baseline and follow-up labs, and be counseled that both agents are not FDA-approved for the purposes described here. CJC-1295 is listed by the FDA as a compounded drug substance subject to regulatory oversight [12]. MK-677 is not FDA-approved for any indication in humans and is classified as an investigational compound [12].

Stacking with Other Peptides or Compounds

Some practitioners add BPC-157 (for tissue repair), Ipamorelin (a cleaner GHRP alternative to replace or supplement CJC-1295's partner agent), or Tesamorelin (an FDA-approved GHRH analogue for HIV-associated lipodystrophy) to create more complex stacks. Adding a second GH secretagogue on top of an already-active CJC-1295 plus MK-677 stack raises IGF-1 further and increases the risk of glucose dysregulation and soft-tissue side effects without proportional benefit for most patients.

Testosterone or TRT does not directly interact with this stack at the receptor level, but GH and testosterone have additive effects on lean mass accrual, so patients on concurrent TRT may see amplified body composition changes and should monitor IGF-1 more frequently [10].

Practical Administration Notes

Injection Technique for CJC-1295

CJC-1295 is supplied as a lyophilized (freeze-dried) powder and reconstituted with bacteriostatic water. Standard reconstitution targets 200 mcg per 0.1 mL to simplify dosing. Inject subcutaneously into the lower abdomen, lateral thigh, or deltoid fat pad, rotating sites to minimize local lipoatrophy. Store reconstituted peptide refrigerated and use within 28 days.

Oral MK-677 Timing

MK-677 is active within 30 to 60 minutes of oral ingestion. Taking it 30 minutes before sleep aligns peak GHS-R1a activation with the first slow-wave sleep cycle, which is when the body's largest natural GH pulse occurs. Avoid taking it with a high-fat meal, which may slow absorption modestly, though no pharmacokinetic data specific to meal composition and MK-677 absorption have been published for humans.

The Nocturnal Pulse Strategy

The most pharmacologically rational approach is to inject non-DAC CJC-1295 (Modified GRF 1-29) at 100 mcg and take MK-677 25 mg simultaneously, 30 minutes before bed. This positions GHRH receptor activation and ghrelin receptor activation to converge on the pituitary at the same time, during the window of lowest somatostatin tone, producing the largest coordinated GH pulse possible with these two agents. Check IGF-1 at week 6. Do not increase doses before that lab result is reviewed.